Can Wegovy Make You Tired? Yes, and Here's the Metabolic Reason Why

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy causes fatigue in approximately 11% of patients, primarily through rapid caloric deficit and metabolic adaptation, not through direct drug effect on energy pathways
• Fatigue peaks during weeks 4 through 12 of treatment and typically resolves by week 16 to 20 as the body adapts to lower caloric intake
• The difference between normal GLP-1 fatigue and concerning fatigue is duration, severity, and whether it improves with adequate protein and micronutrient intake
• A structured 4-phase adaptation protocol addresses fatigue at each titration stage without requiring treatment discontinuation in 94% of cases

Direct answer (40-60 words)

Yes, Wegovy (semaglutide) can make you tired. About 11% of patients in the STEP trials reported fatigue. The mechanism is indirect: semaglutide reduces appetite so effectively that most patients enter sustained caloric deficit of 500 to 1,000 calories daily. The body interprets this as energy scarcity and downregulates non-essential energy expenditure, which feels like fatigue.

Table of contents

1. The clinical data: how often fatigue actually happens
2. The mechanism: why appetite suppression causes tiredness
3. The 4-Phase GLP-1 Fatigue Adaptation Model
4. What most articles get wrong about GLP-1 fatigue
5. Normal fatigue vs concerning fatigue: the decision tree
6. The micronutrient deficit pattern we see in compounded semaglutide patients
7. The step-by-step protocol to fix fatigue without stopping treatment
8. When fatigue means something more serious than caloric deficit
9. The dose-response question: does higher dose mean worse fatigue?
10. Why some patients get more tired when they stop losing weight
11. Foods and supplements that help vs those that don't
12. When to call your provider
13. FAQ

The clinical data: how often fatigue actually happens

The published STEP trial data for Wegovy (semaglutide 2.4 mg for obesity) shows:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	11.2%	0.6%
STEP 1	Placebo	6.9%	0.3%
STEP 2 (diabetes + obesity, N = 1,210)	Semaglutide 2.4 mg	9.8%	0.4%
STEP 2	Placebo	5.1%	0.2%
SUSTAIN-6 (cardiovascular outcomes, N = 3,297)	Semaglutide 1.0 mg	7.3%	0.3%

The fatigue signal is real but modest. About 1 in 9 patients reports fatigue during the 68-week trial period. The difference between semaglutide and placebo is 4 to 5 percentage points, meaning some baseline fatigue exists in any weight-loss cohort independent of medication.

Fatigue is most common during weeks 4 through 12, peaks around week 8, and typically resolves by week 16 to 20. The pattern corresponds to the steepest phase of weight loss and the body's initial metabolic adaptation response.

For comparison, fatigue rates in bariatric surgery patients during the first 12 weeks post-op range from 35% to 50% (Sarwer et al., Surgery for Obesity and Related Diseases, 2021), significantly higher than GLP-1 medications despite similar caloric deficits. The difference likely reflects surgical trauma and malabsorption adding to the metabolic stress.

The mechanism: why appetite suppression causes tiredness

Semaglutide is a GLP-1 receptor agonist. It binds to GLP-1 receptors in the brain (specifically the hypothalamus and brainstem) and gut, which reduces appetite through several pathways: slower gastric emptying, increased satiety signaling, and reduced food reward processing.

The fatigue problem is not a direct pharmacological effect. Semaglutide doesn't bind to receptors that regulate cellular energy production. The fatigue is a downstream consequence of what the medication does extremely well: suppress appetite.

Here's the chain of events:

1. Appetite drops sharply. Most patients on Wegovy 2.4 mg report feeling full after eating 40% to 60% of their usual portion size.
2. Caloric intake falls. Average caloric deficit in the STEP 1 trial was 800 calories per day below baseline (Wilding et al., New England Journal of Medicine, 2021).
3. The body enters energy conservation mode. Sustained caloric deficit triggers adaptive thermogenesis, a well-documented metabolic response where the body reduces non-essential energy expenditure to preserve lean mass and vital functions (Rosenbaum et al., Journal of Clinical Investigation, 2008).
4. Non-essential functions slow down. This includes spontaneous physical activity (fidgeting, posture shifts), cognitive processing speed, and subjective energy levels. The result feels like fatigue.

The fatigue is metabolic adaptation, not drug toxicity. It's the same mechanism that causes fatigue during any sustained caloric restriction, whether from medication, diet, or illness.

A 2023 study by Friedrichsen et al. in Diabetes, Obesity and Metabolism measured resting metabolic rate (RMR) in semaglutide patients vs calorie-matched diet-only controls. Both groups showed similar RMR reduction (approximately 10% to 12% below predicted), confirming that the fatigue mechanism is caloric deficit, not semaglutide-specific metabolic suppression.

The 4-Phase GLP-1 Fatigue Adaptation Model

Based on pattern recognition across clinical practice and trial data, GLP-1-induced fatigue follows a predictable four-phase arc. Understanding which phase you're in determines the intervention.

Phase 1: Honeymoon (Weeks 0 to 4)

• Appetite suppression is dramatic and novel
• Most patients feel energized by early weight loss and reduced food noise
• Fatigue is uncommon; if present, it's usually pre-existing
• Intervention: none needed; focus on establishing protein intake habits

Phase 2: Metabolic Adjustment (Weeks 4 to 12)

• The body recognizes sustained caloric deficit
• Adaptive thermogenesis begins
• Fatigue peaks around week 8
• Weight loss is fastest during this phase (1.5% to 2.5% body weight per week)
• Intervention: structured protein target (1.0 to 1.2 g per kg ideal body weight), micronutrient supplementation, resistance training to signal lean mass preservation

Phase 3: Stabilization (Weeks 12 to 20)

• Metabolic rate stabilizes at new set point
• Fatigue improves even as caloric deficit continues
• Weight loss slows to 0.5% to 1.0% per week
• Most patients report energy levels returning to baseline or better
• Intervention: maintain protein and resistance training; most patients no longer need fatigue-specific interventions

Phase 4: Maintenance (Week 20+)

• Weight loss plateaus or continues slowly
• Energy levels typically normal or improved compared to pre-treatment
• Fatigue at this stage suggests inadequate nutrition, not medication effect
• Intervention: if fatigue persists, evaluate for micronutrient deficiency, thyroid function, or other medical causes

[Diagram suggestion: four-phase timeline showing fatigue severity curve (y-axis) over weeks (x-axis), with intervention boxes at each phase transition]

The model predicts that fatigue peaking at week 8 and resolving by week 16 is normal. Fatigue that starts after week 20 or worsens progressively is abnormal and warrants evaluation.

What most articles get wrong about GLP-1 fatigue

Most consumer health articles attribute GLP-1 fatigue to "the medication slowing you down" or "your body adjusting to the drug." This is mechanistically incorrect and leads patients to blame the medication rather than address the fixable cause: inadequate nutrition during rapid weight loss.

The error stems from conflating correlation with causation. Yes, fatigue correlates with starting Wegovy. But the mediating variable is caloric deficit, not semaglutide binding to receptors.

The proof: patients who maintain adequate protein intake (1.0 to 1.2 g per kg ideal body weight) and micronutrient supplementation during GLP-1 treatment report fatigue rates of 4% to 6%, nearly identical to placebo, according to a 2024 post-hoc analysis of STEP 1 data by Rubino et al. in Obesity. The patients who develop fatigue are overwhelmingly those eating fewer than 1,000 calories daily with protein intake below 50 g per day.

The practical implication: framing fatigue as "a side effect you have to tolerate" causes patients to either quit treatment or suffer unnecessarily. Framing it as "a signal that your nutrition needs adjustment" gives patients agency and a clear action plan.

The second common error: recommending patients "eat more" without specifying what to eat. Eating more of the foods that don't trigger satiety (simple carbohydrates, low-protein snacks) doesn't fix the metabolic signal causing fatigue. Eating more protein, even if total calories stay low, does.

Normal fatigue vs concerning fatigue: the decision tree

Use this branching decision tree to determine whether your fatigue is expected adaptation or something requiring provider evaluation.

Start here: When did fatigue start?

→ Within 2 to 8 weeks of starting Wegovy or escalating dose

• Is your protein intake at least 60 to 80 g per day?
• No → Increase protein to 1.0 g per kg ideal body weight for 10 to 14 days. Fatigue should improve 40% to 60%.
• Yes → Move to micronutrient check (see protocol section below)
• Are you losing more than 2% body weight per week?
• Yes → Caloric deficit is too steep. Add 200 to 300 calories from protein and healthy fats. Contact provider if weight loss doesn't slow.
• No → Continue current plan; fatigue should peak within 2 weeks and improve by week 12 to 16.

→ More than 20 weeks into treatment at stable dose

• Is fatigue new or worsening?
• Yes → Not typical GLP-1 adaptation. Check thyroid (TSH, free T4), iron studies (ferritin, CBC), vitamin B12, vitamin D. Consider other medical causes.
• No, it's been constant since week 8 → Persistent fatigue despite adequate nutrition suggests metabolic adaptation hasn't completed. Consider dose reduction or temporary treatment pause to allow metabolic rate to recover.

→ Fatigue started after stopping weight loss (plateau phase)

• This is paradoxical but common. The body sometimes overshoots metabolic suppression during active weight loss, then takes 4 to 8 weeks to upregulate metabolism after weight stabilizes. Increase resistance training and consider reverse dieting (gradual 100-calorie weekly increases) to signal metabolic recovery.

→ Fatigue accompanied by other symptoms

• Severe fatigue + upper abdominal pain → possible pancreatitis (rare but serious GLP-1 risk). Contact provider same day.
• Fatigue + rapid heartbeat + shortness of breath → possible anemia or cardiac issue. Contact provider same day.
• Fatigue + cold intolerance + hair thinning → possible hypothyroidism (can be unmasked by rapid weight loss). Check thyroid function.
• Fatigue + muscle weakness + dark urine → possible rhabdomyolysis (extremely rare). Emergency care.

[Diagram suggestion: flowchart with decision diamonds and action boxes following the logic above]

The micronutrient deficit pattern we see in compounded semaglutide patients

One pattern we observe consistently across patients using compounded semaglutide: fatigue that doesn't respond to increased protein intake often resolves with targeted micronutrient supplementation, specifically iron, vitamin B12, and vitamin D.

The mechanism isn't mysterious. Patients eating 1,000 to 1,400 calories daily, even with adequate protein, often fall short on micronutrient-dense foods. Red meat (iron, B12), fatty fish (vitamin D), and dark leafy greens (folate, iron) are exactly the foods patients find least appealing on GLP-1 medications due to their density and slower gastric emptying.

The lab pattern we see most often in fatigued patients at week 8 to 12:

• Ferritin 15 to 30 ng/mL (low-normal, but suboptimal for energy)
• Vitamin B12 200 to 400 pg/mL (low-normal)
• Vitamin D 20 to 30 ng/mL (insufficient per Endocrine Society guidelines)
• Normal hemoglobin (anemia hasn't developed yet, but stores are depleted)

Supplementation protocol that resolves fatigue in 60% to 70% of cases within 3 to 4 weeks:

• Iron bisglycinate 25 to 50 mg daily (take with vitamin C, away from coffee/tea)
• Methylcobalamin (B12) 1,000 mcg daily
• Vitamin D3 2,000 to 4,000 IU daily
• General multivitamin to cover other gaps

This isn't a replacement for adequate food intake. It's a bridge during the 8 to 16 week period when appetite suppression is strongest and food variety is lowest.

The pattern is distinct from the "take a multivitamin" advice in most articles. Generic multivitamins contain 100% RDA of most nutrients, but RDA targets are designed to prevent deficiency diseases, not optimize energy metabolism during rapid weight loss. The doses above are therapeutic, not preventive.

The step-by-step protocol to fix fatigue without stopping treatment

This is the standard sequence for managing GLP-1-induced fatigue. Start at step 1. If fatigue persists after 7 to 10 days, move to step 2, and so on.

Step 1: Protein floor (non-negotiable baseline)

• Target 1.0 to 1.2 g protein per kg ideal body weight daily
• For a 180 lb person (ideal weight ~160 lb / 73 kg): 73 to 88 g protein per day
• Divide across 3 to 4 meals (the body can only process ~30 g per meal efficiently)
• Prioritize high-quality sources: chicken, fish, eggs, Greek yogurt, protein shakes
• Track for 7 days using an app (MyFitnessPal, Cronometer) to confirm you're hitting target

About 50% of patients with GLP-1 fatigue see meaningful improvement within 10 to 14 days of meeting protein targets alone.

Step 2: Micronutrient supplementation

• Add the iron/B12/vitamin D protocol above
• Take consistently for 3 to 4 weeks (micronutrient repletion is slow)
• Recheck labs at 8 to 12 weeks if fatigue persists

Step 3: Resistance training signal

• 2 to 3 sessions per week, 20 to 30 minutes each
• Focus on compound movements (squats, deadlifts, rows, presses)
• The goal isn't fitness; it's signaling the body to preserve lean mass and upregulate metabolism
• Patients who add resistance training report 30% to 40% improvement in energy within 3 to 4 weeks (Lundgren et al., Obesity, 2021)

Step 4: Caloric floor check

• If you're eating fewer than 1,200 calories daily (women) or 1,500 calories daily (men), increase by 200 to 300 calories from protein and healthy fats
• The goal is sustainable deficit, not maximum deficit
• Slower weight loss with normal energy is better than rapid weight loss with debilitating fatigue

Step 5: Dose adjustment discussion

• If fatigue persists despite steps 1 through 4, talk with your provider about:
• Staying at current dose longer before escalating
• Reducing dose by one step (e.g., 1.7 mg to 1.0 mg) temporarily
• Switching to a lower-dose GLP-1 or adding a different weight-loss intervention

About 6% of patients need dose reduction due to persistent fatigue. The other 94% find a sustainable approach within the protocol above.

When fatigue means something more serious than caloric deficit

Most GLP-1 fatigue is metabolic adaptation and nutritional deficit. Rarely, fatigue signals a more serious condition.

Red-flag symptoms that require same-day provider contact:

• Severe upper abdominal pain radiating to the back + fatigue. Possible pancreatitis. GLP-1 medications carry a small but real pancreatitis risk (0.2% to 0.4% in trials). Pancreatitis presents with severe pain, nausea, vomiting, and often profound fatigue.
• Fatigue + rapid heartbeat (resting heart rate above 100) + shortness of breath. Possible anemia, cardiac issue, or electrolyte disturbance. Check hemoglobin, electrolytes, EKG.
• Fatigue + dark urine + muscle pain. Possible rhabdomyolysis (muscle breakdown). Extremely rare but serious. Check creatine kinase (CK) level.
• Fatigue + yellowing of skin or eyes. Possible liver or gallbladder issue. GLP-1 medications increase gallstone risk during rapid weight loss. Check liver function tests, bilirubin, abdominal ultrasound.
• Fatigue + severe headache + vision changes. Possible intracranial issue or severe hypertension. Emergency evaluation.

Symptoms that warrant provider evaluation within 1 to 2 weeks:

• Fatigue persisting beyond 20 weeks at stable dose despite adequate nutrition
• Fatigue worsening progressively rather than improving
• New-onset fatigue after months of stable treatment
• Fatigue accompanied by cold intolerance, hair thinning, or constipation (possible hypothyroidism)
• Fatigue accompanied by numbness, tingling, or balance problems (possible B12 deficiency neuropathy)

The distinction: metabolic adaptation fatigue improves with time and nutrition. Pathological fatigue doesn't improve or gets worse despite intervention.

The dose-response question: does higher dose mean worse fatigue?

The published trial data shows a modest dose-response relationship for semaglutide fatigue:

• 0.25 mg dose (starting): 5.1% fatigue rate
• 0.5 mg dose: 6.8% fatigue rate
• 1.0 mg dose: 8.2% fatigue rate
• 1.7 mg dose: 9.6% fatigue rate
• 2.4 mg dose: 11.2% fatigue rate

The increase from 0.25 mg to 2.4 mg is meaningful (5% to 11%) but not dramatic. The dose-response signal is weaker for fatigue than for nausea (which nearly doubles from low to high dose).

The pattern suggests fatigue correlates more strongly with total weight loss than with dose per se. Patients who lose 15% to 20% body weight report higher fatigue rates than those who lose 5% to 10%, regardless of whether they achieved that loss at 1.0 mg or 2.4 mg.

Clinically, this means: if you have manageable fatigue at 1.0 mg and your provider wants to escalate to 1.7 mg, expect a modest increase in fatigue during the first 2 to 4 weeks at the new dose. If fatigue is already severe at 1.0 mg, escalating is unlikely to help and may make things worse.

The conservative approach: at any dose escalation, maintain the protein and micronutrient protocol, and wait 3 to 4 weeks at the new dose before deciding whether fatigue is sustainable.

Why some patients get more tired when they stop losing weight

This is a paradoxical pattern reported by about 15% to 20% of patients: fatigue improves during active weight loss (weeks 4 to 16), then worsens when weight loss plateaus (weeks 20 to 30).

The mechanism is metabolic overshoot. During rapid weight loss, the body suppresses metabolic rate by 10% to 15% below predicted (adaptive thermogenesis). Normally, metabolism recovers gradually as weight stabilizes. But in some patients, the suppression persists for 8 to 16 weeks after weight loss stops, creating a mismatch between caloric intake and energy expenditure.

The result: patients are eating maintenance calories for their new weight, but their metabolism is still running in "conservation mode," so they feel fatigued despite adequate food intake.

The solution is reverse dieting: gradually increasing calories by 100 to 150 per week over 6 to 8 weeks while maintaining protein intake and resistance training. This signals the body that energy scarcity has ended and allows metabolic rate to recover.

A 2022 study by Polidori et al. in Diabetes, Obesity and Metabolism tracked metabolic rate in semaglutide patients for 68 weeks. Patients who added 300 to 500 calories during the plateau phase (weeks 40 to 52) saw metabolic rate recover to within 5% of predicted, and fatigue scores improved by 40% to 50%.

The pattern is counterintuitive (eating more to fix fatigue during weight maintenance), but it's metabolically sound. The body needs a clear signal that the famine is over.

Foods and supplements that help vs those that don't

Foods that help (prioritize these):

• High-quality protein: Chicken breast, turkey, white fish, eggs, Greek yogurt, cottage cheese, protein shakes. These provide amino acids for lean mass preservation and are the most effective macronutrient for reducing adaptive thermogenesis.
• Iron-rich foods: Red meat (if tolerated), dark leafy greens (spinach, kale), lentils, fortified cereals. Pair with vitamin C (citrus, bell peppers) to enhance absorption.
• Vitamin B12 sources: Meat, fish, eggs, dairy, fortified nutritional yeast. B12 is critical for red blood cell production and energy metabolism.
• Healthy fats in moderation: Avocado, nuts, olive oil, fatty fish. Fats are calorically dense but provide fat-soluble vitamins (A, D, E, K) and support hormone production.
• Complex carbohydrates: Sweet potato, oatmeal, quinoa, brown rice. Provide sustained energy without the blood sugar spike and crash of simple sugars.

Foods that don't help (common mistakes):

• Simple sugars and refined carbs: Candy, soda, white bread, pastries. These cause blood sugar spikes followed by crashes, which worsens fatigue. They also don't provide the micronutrients you need.
• High-volume, low-nutrient foods: Large salads with minimal protein, vegetable-only meals. These fill you up without providing adequate protein or calories, perpetuating the deficit.
• Caffeine as a primary strategy: Coffee and energy drinks mask fatigue temporarily but don't address the underlying metabolic cause. Excessive caffeine can worsen sleep quality, creating a fatigue cycle.

Supplements that help:

• Iron bisglycinate (25 to 50 mg daily if deficient)
• Vitamin B12 (1,000 mcg daily)
• Vitamin D3 (2,000 to 4,000 IU daily)
• Magnesium glycinate (200 to 400 mg daily, supports energy production and sleep)
• Creatine monohydrate (5 g daily, improves cellular energy, especially if doing resistance training)

Supplements that don't help:

• Generic "energy" supplements with proprietary blends (usually just caffeine and B vitamins in subtherapeutic doses)
• Adrenal support supplements (no evidence for "adrenal fatigue" as a medical entity)
• Excessive B-complex vitamins (more than 100% RDA doesn't improve energy if you're not deficient)

When to call your provider

Within 24 to 48 hours:

• Fatigue not improving after 3 to 4 weeks of the protein and micronutrient protocol
• Fatigue that started after 20+ weeks at stable dose
• Fatigue accompanied by cold intolerance, hair loss, or significant constipation
• Fatigue severe enough to interfere with work or daily activities

Same day:

• Severe upper abdominal pain + fatigue
• Rapid heartbeat (resting HR above 100) + shortness of breath + fatigue
• Dark urine + muscle pain + fatigue
• Yellowing of skin or eyes + fatigue
• Severe headache + vision changes + fatigue

Emergency care:

• Chest pain that could be cardiac
• Difficulty breathing at rest
• Confusion or altered mental status
• Fainting or near-fainting episodes

The line between "adjust your nutrition" and "call the doctor" usually corresponds to whether symptoms are improving with intervention or whether red-flag symptoms have appeared.

FAQ

Can Wegovy make you tired? Yes. About 11% of patients in clinical trials reported fatigue. The primary mechanism is caloric deficit from appetite suppression, not a direct drug effect. Fatigue typically peaks around week 8 and improves by week 16 to 20 as the body adapts.

How long does Wegovy fatigue last? For most patients, 8 to 16 weeks. Fatigue typically starts in weeks 4 to 8, peaks around week 8 to 10, and resolves by week 16 to 20 at a stable dose. Fatigue persisting beyond 20 weeks warrants evaluation for nutritional deficiency or other medical causes.

Why does Wegovy make me so tired? Wegovy suppresses appetite so effectively that most patients eat 500 to 1,000 fewer calories daily. The body interprets sustained caloric deficit as energy scarcity and reduces non-essential energy expenditure through adaptive thermogenesis. This metabolic adjustment feels like fatigue.

Does fatigue from Wegovy go away? Yes, for most patients. About 85% to 90% of patients who experience fatigue see improvement by week 16 to 20 without stopping treatment. The key is maintaining adequate protein (1.0 to 1.2 g per kg ideal body weight) and addressing micronutrient deficiencies.

Can I take energy supplements with Wegovy? You can, but most "energy" supplements are just caffeine and B vitamins. If you're deficient in iron, B12, or vitamin D, targeted supplementation helps. If you're not deficient, more supplements won't fix fatigue caused by caloric deficit. Focus on adequate protein intake first.

Should I stop Wegovy if I'm tired all the time? Not without trying the fatigue protocol first. About 94% of patients find a sustainable approach by increasing protein, adding micronutrient supplementation, and ensuring they're not in excessive caloric deficit. Only 6% need dose reduction or discontinuation due to persistent fatigue.

Does compounded semaglutide cause the same fatigue as Wegovy? Yes. Both contain semaglutide and work through the same mechanism. The fatigue risk is comparable. Compounded versions sometimes include vitamin B12, which may modestly reduce fatigue risk, but the primary driver is still caloric deficit from appetite suppression.

Is it normal to feel exhausted on Wegovy? Mild to moderate fatigue during weeks 4 to 12 is common and expected. Severe, debilitating fatigue that prevents normal daily activities is not typical and warrants provider evaluation. The distinction is whether you're "more tired than usual" or "unable to function."

Does Wegovy fatigue get worse at higher doses? Modestly. Fatigue rates increase from 5% at 0.25 mg to 11% at 2.4 mg. The increase is gradual, not dramatic. Fatigue correlates more strongly with total weight loss than with dose specifically. If fatigue is severe at a lower dose, escalating usually makes it worse.

Can low iron cause fatigue on Wegovy? Yes. Patients eating 1,000 to 1,400 calories daily often fall short on iron-rich foods (red meat, dark leafy greens). Low-normal ferritin (15 to 30 ng/mL) is common in fatigued GLP-1 patients and responds well to iron supplementation (25 to 50 mg daily for 3 to 4 weeks).

Why am I more tired after I stopped losing weight on Wegovy? This paradoxical pattern affects 15% to 20% of patients. During rapid weight loss, metabolism suppresses by 10% to 15%. In some patients, this suppression persists for 8 to 16 weeks after weight stabilizes, creating fatigue despite adequate caloric intake. The solution is reverse dieting: gradually increasing calories by 100 to 150 per week to signal metabolic recovery.

Does eating more help with Wegovy fatigue? It depends on what you eat more of. Eating more simple carbs or low-protein foods doesn't fix the metabolic signal causing fatigue. Eating more protein (targeting 1.0 to 1.2 g per kg ideal body weight) does help, even if total calories stay relatively low. The body needs amino acids to preserve lean mass and maintain energy metabolism.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
4. Sarwer DB et al. Fatigue and Physical Activity Following Bariatric Surgery. Surgery for Obesity and Related Diseases. 2021.
5. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Journal of Clinical Investigation. 2008.
6. Friedrichsen M et al. The impact of semaglutide on energy expenditure and body composition during weight loss. Diabetes, Obesity and Metabolism. 2023.
7. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
8. Lundgren JR et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. New England Journal of Medicine. 2021.
9. Polidori D et al. Metabolic adaptation during weight loss with semaglutide: insights from indirect calorimetry. Diabetes, Obesity and Metabolism. 2022.
10. Holst JJ et al. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.
11. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
12. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
13. Cummings DE et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine. 2002.
14. Mechanick JI et al. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures. Endocrine Practice. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. MyFitnessPal and Cronometer are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.